Table 1. Patient clinical, demographic and neuropsychological data.
| Age/sex | Handedness | Epilepsy onset (y) | Seizure types and frequency (per month) | Postop outcome (ILAE class) | MRI and pathological diagnosis | Clinical and EEG | Preop naming (centile) | Postop naming (centile) | Naming change | AEDs (mg/day) | LD |
| 37/M | Left | 1 | SPS 12 CPS 4 | 2 | Left HS | Left TLE | 19 (50th) | 16 (25th) | −3 | VPA 800 CBZ 800 LVT 2000 | Left |
| 33/M | Right | 1 | SPS 4 CPS 4 | 1 | Left HS | Left TLE | 13 (5th) | 15 (10th) | 2 | PMD 500 CBZ 1200 CLB 10 TPR 175 LVT 4000 | Left |
| 25/F | Right | 17 | CPS 8 SGTC 0.5 | 1 | Left HS | Left TLE | 7 (<1st) | 5 (<1st) | −2 | TPR 150 LTG 300 | Left |
| 28/M | Right | 3 | CPS 1 | 1 | Left HS | Left TLE | 4 (<1st) | 7 (<1st) | 3 | LVT 3000 LTG 600 | Left |
| 31/M | Right | 10 | CPS 50 SGTC 3 | 1 | Left MTL DNET | Left TLE | 14 (10th) | 10 (<1st) | −4 | CBZ 1200 CLN 1.5 LTG 100 | Left |
| 37/F | Right | 1 | SPS 12 CPS 8 SGTC 1 | 3 | Left HS, left fusiform gyrus ganglioglioma | Left TLE | 10 (<1st) | 13 (5th) | 3 | CBZ 1000 CLB 10 | Left |
| 36/M | Left | 15 | SPS 6 CPS 6 SGTC 3 | 1 | Right MTL glioma | Right TLE | 17 (25th) | 2 (<1st) | −15 | CBZ 1600 CLB 20 LTG 400 | Right |
AED, antiepileptic drug; CBZ, carbamazepine; CLB, clobazam; CLN, clonazepam; CPS, complex partial seizure; DNET, dysembryoplastic neuroepithelial tumour; HS, hippocampal sclerosis; ILAE, International League Against Epilepsy; LD, language dominance; LTG, lamotrigine; LVT, levetiracetam; MTL, medial temporal lobe; NA, not applicable; PMD, primidone; SGTC, secondary generalised tonic–clonic seizure; SPS, simple partial seizure; TLE, temporal lobe epilepsy; TPR, topiramate; VPA, sodium valproate.